NEW YORK, April 2, 2013 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that DiagnoCure Inc. (OTCQX: DGCRF; TSX: CUR), a life sciences company that develops and commercializes high-value cancer diagnostic tests, has chosen to trade on OTCQX®, the best OTC marketplace with qualified companies.
DiagnoCure will begin trading today on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies listed on a qualified stock exchange in their home country. Investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased DiagnoCure has chosen to trade on OTCQX," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "OTCQX is the highest OTC marketplace offering qualifying companies the means to grow their U.S. shareholder base through high-quality disclosure, transparent trading and ease of access to company information.""We are proud to join OTCQX, which will enable us to provide our U.S. investors with timely news and information to help them better analyze, value and trade our securities," said Chantal Miklosi, Chief Financial Officer of DiagnoCure. Dorsey & Whitney LLP will serve as DiagnoCure's Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws. DiagnoCure is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. Previstage ™ GCC is currently available for licensing. The company has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the development and commercialization of prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. DiagnoCure trades in the U.S. on OTCQX under the symbol "DGCRF."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts